Table 3.
Correlations between CTA expression and clinicopathological features
| Variables | Sex
|
P | Age (years)
|
P | Smoking history
|
P | Pathological types
|
P | TNM stage
|
P | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | <65 | ≥65 | No | Yes | ADC | SCC | IIIA | IIIB | ||||||
|
| |||||||||||||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
| MAGEA1 | 0.583 | 0.413 | 0.812 | 0.248 | 0.077 | ||||||||||
| Negative | 51 (38.6) | 29 (42.6) | 63 (38.7) | 17 (45.9) | 30 (39.0) | 50 (40.7) | 36 (36.0) | 44 (44.0) | 56 (36.6) | 24 (51.1) | |||||
| Positive | 81 (61.4) | 39 (57.4) | 100 (61.3) | 20 (54.1) | 47 (61.0) | 73 (59.3) | 64 (64.0) | 56 (56.0) | 97 (63.4) | 23 (48.9) | |||||
| MAGEA3 | 0.570 | 0.549 | 0.832 | 0.006 | 0.448 | ||||||||||
| Negative | 100 (75.8) | 49 (72.1) | 120 (73.6) | 29 (78.4) | 58 (75.3) | 91 (74.0) | 66 (66.0) | 83 (83.0) | 112 (73.2) | 37 (78.7) | |||||
| Positive | 32 (24.2) | 19 (27.9) | 43 (26.4) | 8 (21.6) | 19 (24.7) | 32 (26.0) | 34 (34.0) | 17 (17.0) | 41 (26.8) | 10 (21.3) | |||||
| MAGEA10 | 0.136 | 0.856 | 0.059 | 0.002 | 0.404 | ||||||||||
| Negative | 71 (53.8) | 29 (42.6) | 82 (50.3) | 18 (48.6) | 32 (41.6) | 68 (55.3) | 39 (39.0) | 61 (61.0) | 74 (48.4) | 26 (55.3) | |||||
| Positive | 61 (46.2) | 39 (57.4) | 81 (49.7) | 19 (51.4) | 45 (58.4) | 55 (44.7) | 61 (61.0) | 39 (39.0) | 79 (51.6) | 21 (44.7) | |||||
| MAGEB2 | 0.086 | 0.636 | 0.045 | 0.026 | 0.139 | ||||||||||
| Negative | 81 (61.4) | 50 (73.5) | 108 (66.3) | 23 (62.2) | 57 (74.0) | 74 (60.2) | 73 (73.0) | 58 (58.0) | 96 (62.7) | 35 (74.5) | |||||
| Positive | 51 (38.6) | 18 (26.5) | 55 (33.7) | 14 (37.8) | 20 (26.0) | 49 (39.8) | 27 (27.0) | 42 (42.0) | 57 (37.3) | 12 (25.5) | |||||
| MAGEC1 | 0.012 | 0.421 | 0.003 | <0.001 | 0.050 | ||||||||||
| Negative | 79 (59.8) | 28 (41.2) | 85 (52.1) | 22 (59.5) | 31 (40.3) | 76 (61.8) | 37 (37.0) | 70 (70.0) | 76 (49.7) | 31 (66.0) | |||||
| Positive | 53 (40.2) | 40 (58.8) | 78 (47.9) | 15 (40.5) | 46 (59.7) | 47 (38.2) | 63 (63.0) | 30 (30.0) | 77 (50.3) | 16 (34.0) | |||||
| XAGE1 | 0.011 | 0.849 | 0.037 | <0.001 | 0.689 | ||||||||||
| Negative | 92 (69.7) | 35 (51.5) | 103 (63.2) | 24 (64.9) | 42 (54.5) | 85 (69.1) | 51 (51.0) | 76 (76.0) | 96 (62.7) | 31 (66.0) | |||||
| Positive | 40 (30.3) | 33 (48.5) | 60 (36.8) | 13 (35.1) | 35 (45.5) | 38 (30.9) | 49 (49.0) | 24 (24.0) | 57 (37.3) | 16 (34.0) | |||||
| KK-LC-1 | 0.324 | 0.834 | 0.902 | 0.887 | 0.075 | ||||||||||
| Negative | 66 (50.0) | 39 (57.4) | 85 (52.1) | 20 (54.1) | 40 (51.9) | 65 (52.8) | 52 (52.0) | 53 (53.0) | 75 (49.0) | 30 (63.8) | |||||
| Positive | 66 (50.0) | 29 (42.6) | 78 (47.9) | 17 (45.9) | 37 (48.1) | 58 (47.2) | 48 (48.0) | 47 (47.0) | 78 (51.0) | 17 (36.2) | |||||
| CTAG1A/B | 0.104 | 0.717 | 0.124 | <0.001 | 0.120 | ||||||||||
| Negative | 91 (68.9) | 39 (57.4) | 105 (64.4) | 25 (67.6) | 45 (58.4) | 85 (69.1) | 50 (50.0) | 80 (80.0) | 95 (62.1) | 35 (74.5) | |||||
| Positive | 41 (31.1) | 29 (42.6) | 58 (35.6) | 12 (32.4) | 32 (41.6) | 38 (30.9) | 50 (50.0) | 20 (20.0) | 58 (37.9) | 12 (25.5) | |||||
| VCX1 | 0.740 | 0.740 | 0.262 | 0.426 | 0.092 | ||||||||||
| Negative | 98 (74.2) | 49 (72.1) | 119 (73.0) | 28 (75.7) | 60 (77.9) | 87 (70.7) | 76 (76.0) | 71 (71.0) | 108 (70.6) | 39 (83.0) | |||||
| Positive | 34 (25.8) | 19 (27.9) | 44 (27.0) | 9 (24.3) | 17 (22.1) | 36 (29.3) | 24 (24.0) | 29 (29.0) | 45 (29.4) | 8 (17.0) | |||||
| VCX3A | 0.647 | 0.100 | 0.361 | 0.339 | 0.166 | ||||||||||
| Negative | 95 (72.0) | 51 (75.0) | 123 (75.5) | 23 (62.2) | 59 (76.6) | 87 (70.7) | 76 (76.0) | 70 (70.0) | 108 (70.6) | 38 (80.9) | |||||
| Positive | 37 (28.0) | 17 (25.0) | 40 (24.5) | 14 (37.8) | 18 (23.4) | 36 (29.3) | 24 (24.0) | 30 (30.0) | 45 (29.4) | 9 (19.1) | |||||
Note: The significance of the bold numbers represents that cancer/testis antigen expression is closely correlated with the related clinicopathological characteristics, and this content is listed in the result part of “Relationship between CTA expression and clinicopathological features”.
Abbreviations: CTA, cancer/testis antigen; ADC, adenocarcinoma; SCC, squamous cell carcinoma.